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Abstract 
Photoacoustic imaging (PAI) is an emerging biomedical imaging technique that is now coming to the 
clinic. It has a penetration depth of a few centimeters and generates useful endogenous contrast, 
particularly from melanin and oxy-/deoxyhemoglobin. Indocyanine green (ICG) is a Food and Drug 
Administration-approved contrast agents for human applications, which can be also used in PAI. It is 
a small molecule dye with limited applications due to its fast clearance, rapid protein binding, and 
bleaching effect.  
Methods: Here, we entrap ICG in a poly(lactic-co-glycolic acid) nanoparticles together with a 
perfluorocarbon (PFC) using single emulsion method. These nanoparticles and nanoparticle-loaded 
dendritic cells were imaged with PA, 19F MR, and fluorescence imaging in vitro and in vivo.  
Results: We formulated particles with an average diameter of 200 nm. The encapsulation of ICG 
within nanoparticles decreased its photobleaching and increased the retention of the signal within 
cells, making it available for applications such as cell imaging. As little as 0.1x106 cells could be 
detected in vivo with PAI using automated spectral unmixing. Furthermore, we observed the 
accumulation of ICG signal in the lymph node after subcutaneous injection of nanoparticles.  
Conclusion: We show that we can label primary human dendritic cells with the nanoparticles and 
image them in vitro and in vivo, in a multimodal manner. This work demonstrates the potential of 
combining PAI and 19F MRI for cell imaging and lymph node detection using nanoparticles that are 
currently produced at GMP-grade for clinical use. 
Key words: nanoparticles, multimodal imaging, perfluoro-15-crown-5-ether, indocyanine green, 19F MRI 
Introduction 
Photoacoustic imaging (PAI), also called 
optoacoustic imaging, is a rapidly growing imaging 
technique in biology and medicine thanks to its 
unique ability to image optical contrast at depths of a 
few centimeters with the resolution of ultrasound, a 
combination never before available for optical 
imaging. PAI is based on the thermoelastic effect, 
where absorption of pulsed light by endogenous or 
exogenous chromophores leads to instantaneous 
volume expansion due to transfer of light energy into 
thermal energy, resulting in generation of acoustic 
waves at megahertz frequencies.1,2 These waves are 
detected by an ultrasound transducer and 
reconstructed to form an image of the adsorbed 
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optical energy.3 PAI has been utilized with success for 
a variety of biomedical applications, such as the 
measurement of angiogenesis and blood oxygen 
saturation,4 detection of metastasis in melanoma 
patients,5 breast imaging,6 synovitis in finger joint,7 
needle guidance,8 and preclinical imaging of specific 
tumor cell types with the use of targeted 
nanoparticles.9 Furthermore, PA molecular imaging 
can visualize and quantify physiological processes 
non-invasively at molecular and cellular levels which 
may provide an opportunity to detect stage, as well as 
predict and monitor the development of disease.10  
There are several endogenous chromophores 
exploited by photoacoustic molecular imaging, 
including melanin, oxy- and deoxyhemoglobin, and 
lipids.11 However, despite their intense optical 
absorption, these chromophores provide access to 
limited range of biological processes, often with 
variations and inconsistency in many physiological or 
pathological cases. The use of exogenous agents, 
therefore, could unlock the understanding of 
unlimited disease processes and provide a signal at 
depths not possible with naturally occurring 
chromophore. Exogenous contrast agents with strong 
absorption in the near infrared (NIR) region, where 
biological tissues are relatively transparent and 
optical attenuation is weaker, are being intensively 
investigated. They can be divided into several major 
groups, as reviewed elsewhere11,12: organic dyes, 
fluorescent proteins, metallic and semiconducting 
nanostructures13,14, organic nanostructures, and 
multimodal agents. 
Small molecule NIR dyes are the first class of 
photoacoustic contrast agents as they are readily 
commercially available. Indocyanine green (ICG) is a 
US Food and Drug Administration-approved dye 
with low toxicity, and can be used for both 
fluorescence and photoacoustic imaging.11 In aqueous 
solution, ICG has the maximum absorption at 780 nm 
and a relatively low quantum yield for fluorescence.11 
ICG shows high plasma protein binding and it has 
been used for rapid blood volume measurements, 
angiography, ophthalmology, and sentinel lymph 
node detection.15 Nevertheless, ICG can be rapidly 
cleared from the blood stream and lacks targeting 
abilities. Several research groups have been 
developing contrast agents encapsulating ICG for 
pre-clinical investigation to overcome these 
limitations, for example phase-shift PFC droplets16 or 
PFC double emulsions, although these agents are not 
suitable for 19F MRI or cell labelling. Overall, despite 
the large variety of contrast agents being developed 
and investigated in several applications, there is still a 
lack of reliable and effective contrast agents approved 
for clinical use. 
In this work, we report on polymeric 
nanoparticles encapsulating an imaging agent that 
has been recently approved for a clinical trial for in 
vivo cell tracking of cell therapies (ClinicalTrials.gov 
Identifier: NCT02574377). These nanoparticles consist 
of poly(D,L-lactic-co-glycolic acid) (PLGA) entrapping 
perfluoro-15-crown-5-ether (PFCE) and ICG dye. Due 
to its 20 chemically and magnetically equivalent 
fluorine nuclei, PFCE has been applied as an imaging 
label for 19F MRI.17 We have previously reported on 
the use of PFCE-loaded nanoparticles as 19F MRI 
contrast agents.18–22 Here, we investigate their 
photoacoustic effect and their use as in vivo 
multimodal contrast agents for PA and fluorescence 
through incorporated ICG, and 19F MR through the 
PFCE. PFCE-loaded nanoparticles are of special 
interest as their size and surface chemistry can be 
modified, e.g. with antibodies for targeting therapy 
and delivery.20,21 Thus, we effectively combine the 
ease and sensitivity of PAI with the penetration and 
quantitative capabilities of the slower 19F MRI. In this 
study, we first characterize the PLGA-PFCE-ICG 
nanoparticles and compare their optical absorption 
stability with free ICG dye, then perform PA 
measurements of nanoparticles in vitro in a gel 
phantom and in vivo either after direct injection in a 
murine thigh muscle or in lymph nodes after 
subcutaneous injection. We also demonstrate the 
multimodality aspect of the nanoparticles and, finally, 
we investigate the PA signal detection and intensity of 
primary human monocyte-derived dendritic cells 
(DCs) loaded with nanoparticles, both in vitro and in 
vivo.  
Results  
Characterization of nanoparticles and their 
photoacoustic properties  
PLGA-PFCE-ICG nanoparticles (Fig.1A) were 
synthesized using a miniemulsion method and 
characterized with several techniques to determine 
their physical properties. We were able to synthesize 
nanoparticles with an average hydrodynamic 
diameter of 200 nm (range of 100-400 nm) and a 
relatively narrow size distribution measured using 
Dynamic Light Scattering (DLS) (Fig. 1B). With 
cryogenic Scanning Electron Microscopy (cryoSEM) 
we further looked at the size as well as the 
morphology of the nanoparticles (Fig. 1C). CryoSEM 
results show the presence of smaller and larger 
particles with an average diameter of 210 nm ±58 nm 
(100 nanoparticles counted). PFCE encapsulation was 
at 1.1x1019 19F’s per mg of nanoparticles (NMR 
spectrum of PFCE shown in Fig.1D). The 
encapsulation efficiency of ICG was at 33% (0.0022 mg 
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± 0.001 mg ICG per 1 mg of nanoparticles). 
Furthermore, we measured PLGA-PFCE-ICG 
nanoparticles with fluorescence imaging and detected 
strong fluorescence signal (Fig. 1E). To confirm the 
clinical applicability of the PLGA-PFCE-ICG 
nanoparticles imaging platform, we imaged a 
phantom with a clinically applicable concentration of 
nanoparticles on a clinical MRI setup. The 
concentration of nanoparticles was based on previous 
labeling results.19 The phantom, with a clinically 
applicable 19F concentration, was imaged with a SNR 
of 2.7 (Sphantom/Snoise) within 6:30 min on a 3 T human 
scanner (Fig. 1F). 
To determine the photoacoustic properties of 
PLGA-PFCE-ICG nanoparticles, we resuspended 
nanoparticles in a phosphate buffered saline at pH 7.4 
and placed samples in a gel phantom. We compared 
the results to free ICG dye at the same concentration. 
The result presented in Fig. 1E shows a small 
hypsochromic shift of the absorption maximum of 
nanoparticles from 805 nm to 795 compared to free 
ICG. This change can be attributed to possible small 
concentration differences between both samples, since 
it is known that absorption peak of ICG can be 
affected by the changes in its concentration or by 
changes in the chemical environment of the dye.23 
Nevertheless, the nanoparticles had a clear absorption 
peak, which was in accordance with the standard 
absorption peak of ICG in aqueous solution, 
indicating its successful incorporation in the particles.  
We have previously shown the relation between 
nanoparticle concentration and fluorine signal with 
MRI,22 therefore here we focus on PAI. As the 
absorption peak amplitude or PA signal intensity can 
change with the concentration of dye, we measured 
different concentrations of nanoparticles in a gel 
phantom and examined the generated contrast. Fig. 2A 
shows the maximum signal amplitude of a gelatin 
phantom filled with different concentrations of 
PLGA-PFCE-ICG nanoparticles at 800 nm. The 
corresponding PA amplitude as the function of the 
concentration is exhibiting an excellent linear 
relationship (R2=0.98) (Fig. 2A). Furthermore, we 
compared the stability of PLGA-PFCE-ICG 
nanoparticles with free ICG dye. Nanoparticles and a 
solution of free ICG dye, which matched the 
concentration of the dye in particles, were placed in a 
tube and imaged continuously for 10 minutes at 800 nm 
(Fig. 2B). The PA signal of free ICG dye decreased by 
63% in about 2 minutes, while the signal of 
PLGA-PFCE-ICG nanoparticles after 2 minutes of 
irradiation decreased by 25% and was still above 
background level at 10 minutes. This behavior indicates 
that encapsulation strongly decreases the bleaching 
effect of the ICG dye, and thus increases the effective 
length of time in which the imaging agent can be 
followed.  
 
 
Fig. 1. Nanoparticle characterization. (A) The structures of main components of nanoparticles. (B) Size distribution based on dynamic light scattering measurement (C) 
Cryogenic Scanning Electron Microscopy (D) 19F NMR spectrum of PLGA-PFCE-ICG nanoparticles in D2O, here Trifluoroacetic acid (TFA) was used as a reference. (E) 
Fluorescence image of nanoparticles at the concentration of 10 mg/ml. Nanoparticles were excited at 745 nm (F) 19F MR image of 1 mg/ml nanoparticles in a phantom acquired 
on a clinical scanner (false color). (G) PA spectrum of nanoparticles and free ICG dye measured in vitro.  
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Fig. 2. Influence of nanoparticle concentration and nanoparticle stability for PAI. (A) Graph showing the relationship between PA signal nanoparticle concentration, together with 
images showing the signal intensity of nanoparticles at various concentrations (mg/mL). The numbers in the panel represent the concentration in mg/mL. (B) Signal stability of 
PLGA-PFCE-ICG nanoparticles and free ICG dye over 10 minutes of continuous PAI, with the dye at the same concentration in both. 
 
Multimodal in vivo detection of 
PLGA-PFCE-ICG nanoparticles  
The ability to detect nanoparticles PA signal in 
vivo was tested with intramuscular injections of 3 mg 
of PFCE-ICG nanoparticles followed by imaging. The 
injections were done under ultrasound guidance, 
which allowed us to clearly visualize the 
administration of nanoparticles into the tissue (Video 
S1). After injection, we imaged the injected area first 
with PA, and then with fluorescence and 19F MR 
imaging (Fig. 3). Using PA spectroscopy with spectral 
unmixing, the signal from nanoparticles was extracted 
and separated from endogenous chromophores, such 
as oxy- and deoxyhemoglobin (Fig. 3A). 3D 
distribution of the ICG signal in the tissue, which was 
spread over a large area of the muscle, was also 
acquired (Video S2). Furthermore, we imaged the 
mouse with 19F MRI and, as shown in Fig. 3A, the 
fluorine signal (in false color) was clearly visible in the 
thigh muscle of the mouse, which we then 
superimposed over the anatomic proton scan 
(grayscale). 19F MRI was possible due to the high 
encapsulation of PFCE within nanoparticles (1.1x1019 
F’s/mg particles). Finally, to confirm the results from 
PAI and MRI, mice were imaged with fluorescence, 
where the radiant efficiency of the signal coming from 
particles was at around 1-5x107 (Fig. 3A). In all cases, a 
clear signal from the nanoparticles was visible, 
demonstrating in vivo multimodal imaging. 
Free nanoparticle accumulation in the draining 
lymph node  
To demonstrate the ability of PLGA-PFCE-ICG 
nanoparticles to accumulate in a lymph node near the 
injection site, and the possibility to use these 
nanoparticles for cell tracking, we injected 3 mg of 
nanoparticles in the right footpad of a mouse. We then 
performed photoacoustic spectroscopy measurement 
of the popliteal lymph node, where we used a range 
of wavelengths around the ICG peak in the NIR 
range. Before nanoparticle administration, a PA 
baseline image was obtained where no lymph node 
was visible. 30 min after the injection of the 
nanoparticles, we detected the PLGA-PFCE-ICG 
nanoparticle signal in the popliteal lymph node (Fig 
3B). With the use of automated spectral unmixing, we 
extracted the ICG signal in the lymph node from the 
surrounding tissue. The magnitude of the PA signal 
further increased 4 h post-injection, reflecting 
progressive accumulation of nanoparticles in the 
draining lymph node (Fig. 3C). Subsequently, we then 
performed a 3D scan of the tissue containing the 
lymph node at 4 hours to image nanoparticle 
distribution (Video S3).  
In vivo imaging of cells loaded with 
PLGA-PFCE-ICG nanoparticles 
The possibility to image human DCs loaded with 
PLGA-PFCE-ICG nanoparticles using PA was initially 
investigated in a gel phantom prior to in vivo imaging. 
1x106 nanoparticle-loaded DCs were placed in a gel 
phantom and imaged. Compared to free 
nanoparticles, we observed a broader peak at 800 nm 
(Fig.4B) probably due to particle internalization (Fig. 
4A). It has been previously described, that in tissue 
and cells, the ICG emission peak is slightly shifted to 
longer wavelengths.24,25  
Following the phantom measurements, we 
injected PLGA-PFCE-ICG nanoparticle-loaded cells 
into a thigh muscle of a mouse and performed PA 
spectroscopy imaging, where we also detected the 
absorption peak at 800 nm (Video S4). Additionally, 
we examined the ability of PAI to detect a low number 
of nanoparticle-loaded cells by injecting cells at 
various concentrations (0.1x106 and 1x106) 
intramuscularly in vivo, shown in Fig. 4C. With PAI 
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we were able to detect as little as 0.1x106 
nanoparticle-loaded cells, with the PA average at 0.77 
(a.u.). We then confirmed the PA data with the 
fluorescence imaging, where we could also image all 
three concentrations of nanoparticle-loaded cells (Fig. 
4C). 19F MRI data has been previously shown on 
labeled DCs with the same nanoparticles.18,19,22,26 
Nevertheless, to confirm the multimodality of 
PLGA-PFCE-ICG nanoparticles, we also imaged 
0.1x106 and 1x106 nanoparticle-loaded cells with 19F 
MRI after tissue injection (Fig. 4C).  
Nanoparticle signal retention in DCs 
To study the retention of the PLGA-PFCE-ICG 
nanoparticle signal in DCs, we incubated the cells 
with the label for various time points. We then 
measured the signal coming from the 
nanoparticle-loaded cells with fluorescence imaging 
and flow cytometry. The results of fluorescence 
imaging, show a clear signal of 0.7x106 cells, both 
directly after the incubation of the cells with the label, 
and 24 h after further incubation in fresh medium 
(Fig. S1A). The first flow cytometry results show 
retention of the signal up to 48 h of incubation after 
the removal of the label (Fig. S1B), with the small 
decrease in the signal at day 2. In the second 
experiment, we incubated the cells with the label for 3 
different time points. Part of the cells were incubated 
for additional 24 h in fresh medium. With the analysis 
using flow cytometer, we observed that the longer 
incubation of DCs with nanoparticles did not affect 
the signal intensity (Fig. S1C). After 24 h of additional 
 
Fig. 3. In vivo multimodal detection of PLGA-PFCE-ICG nanoparticles. (A) Multimodal imaging (PA, US, 19F MRI and fluorescence) of PLGA-PFCE-ICG nanoparticles injected into 
a thigh muscle of a mouse. The signal coming from the nanoparticles is clearly detectable with all imaging modalities. (n=3) (B) Nanoparticles detection in popliteal lymph node 
at 4 hours’ time point. (C) PLGA-PFCE-ICG nanoparticles were injected into a mouse foot pad and the popliteal lymph node was imaged 30 and 240 minutes after injection. PA 
signal in the node increased from 1.0 PA average amplitude at 30-minute time point to 1.97 PA average amplitude at 4-hour time point at the absorption peak. 
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incubation, the signal intensity of nanoparticle- 
positive cells slightly decreased.  
Discussion 
We have previously shown that PLGA-PFCE 
nanoparticles are suitable for cell loading, and do not 
affect cell properties, such as migration, maturation or 
functionality,18,20,22 and can be successfully used even 
for the simultaneous in vivo visualization of two types 
of primary human DC subsets using 19F MRI.19 
However, given that no single imaging modality is 
perfect, a multimodal approach is most effective. To 
overcome the limitations of single imaging technique 
one can use an approach where a high sensitivity and 
a high temporal and spatial resolution modalities are 
combined, for example.27 Such an approach requires 
the use of contrast agents, which will be applicable for 
multiple imaging techniques.27–30 In this study, we 
have demonstrated the use of our nanoparticles, as a 
multimodal contrast agent in vivo, where the PFCE 
and ICG content allowed their visualization in PA, 19F 
MR, and fluorescence imaging. 
There are several other studies focusing on the 
use of PFCs in a form of phase-shift droplets or 
nanoemulsions for US and PA imaging.31–34 The PFCs 
typically used in these studies are liquids with a low 
boiling point, which undergo a phase shift-change 
upon exposure to high intensity optical or acoustic 
pulse and produce microbubbles, resulting in an 
increase in imaging contrast and release of optical 
contrast.31 Nonetheless, despite the excellent acoustic 
properties, low boiling point PFC nanoemulsions are 
 
Fig. 4. In vivo multimodal imaging of cells loaded with nanoparticles. (A) Representative confocal microscopy image of DCs loaded with particles (white arrows), indicating their 
intracellular localization. (B) PA spectroscopy measurement in a gel phantom of nanoparticle-loaded cells (1x106 cells) and free nanoparticles. (C) Different concentrations of 
nanoparticle-loaded cells were injected intramuscularly in vivo and imaged with PAI and fluorescence (n=3). PA data was spectrally unmixed, with green indicating the labeled cells, 
red oxyhemoglobin and blue deoxyhemoglobin. Furthermore, nanoparticle-loaded cells were injected into the thigh muscle and imaged with 19F MRI (n=1). 
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unstable for storage, and can already show the 
irreversible droplet-to-bubble transition upon 
injection.35–37 The vaporization makes them unsuitable 
for 19F MRI and intracellular loading. Furthermore, 
after phase shift, these microbubbles will dissolve 
quite fast precluding longitudinal imaging. Our 
nanoparticles encapsulate a high boiling point PFCE 
(145 °C) with which we do not observe any 
vaporization upon acoustic exposure. We also show 
that the encapsulation of ICG in the nanoparticles 
enhances ICG photostability (Fig. 2B). ICG 
encapsulated in nanoparticles is protected from the 
surrounding environment and water diffusion, which 
results in enhanced ICG circulatory life time, slower 
protein binding, and better dye stability.15,25  
In general, the size of our nanoparticles should 
allow the particles to extravasate and accumulate in 
tumors via the enhanced permeability and retention 
(EPR) effect38,39 thanks to the cell junction gaps which 
typically range between 100 and 800 nm.40,41 
However, in case of particles larger than 100 nm it 
may be necessary to further functionalize these 
nanoparticles with targeting moieties to avoid 
clearance via the reticuloendothelial system. The 
targeting of PLGA nanoparticles should be relatively 
easy and has been reviewed extensively,42,43 while 
functionalization and targeting of free ICG dye are 
difficult. After freeze-drying, PLGA-PFCE-ICG 
nanoparticles are stable for storage for at least several 
months, which makes them attractive for clinical use 
as they are readily accessible and easy to transport. 
Furthermore, the stability of PLGA-PFCE-ICG 
nanoparticles allows for longer imaging times, which 
is beneficial for in vivo cell imaging, e.g. in 
applications involving cell tracking.22 Both in vitro and 
in vivo PA measurements of nanoparticles in gel 
phantom showed strong contrast and a sharp 
absorption peak, proving that PLGA-PFCE-ICG 
nanoparticles can be used as contrast agents for PAI, 
as they can be easily distinguished from the 
endogenous signal of hemoglobin. Additionally, the 
fact that we were able to detect 19F MR signal after 
imaging with US and PA confirms lack of PFCE 
vaporization after acoustic exposure. 
The detection and staging of lymph nodes, 
especially for the tumor draining sentinel lymph node 
(SLN), are of high importance for clinical cancer 
diagnosis and intervention. The current clinical 
approach to identify SLN invasively uses a colloid of 
radionuclide or subcutaneous injection of a dye in 
tissue prior to surgery.44 Fluorescent dyes are also 
used to stage SLN, however, they exhibit small 
molecular size which makes their retention in the SLN 
difficult. Furthermore, they pass quickly to the next 
node leading to difficulty in distinguishing SNL from 
other nodes.44 The solution to this problem lies in the 
use of nanoparticles with an encapsulated dye. Here, 
we showed the potential of using the developed 
nanoparticles to perform SLN staging using PAI. The 
experiment showed an accumulation of signal in the 
LN upon subcutaneous footpad injection of the 
nanoparticles. The signal increased over time which 
demonstrates a retention for a period long enough for 
surgery to be performed.  
Current studies on PA contrast agents for cell 
imaging focus on the use of gold (Au) nanoparticles, 
Au nanorods, and single walled carbon nanotubes 
(SWNTs).45 For example, Au nanoparticles and 
nanorods have been applied for the imaging and 
tracking of mesenchymal stem cells in vivo.27,46 Despite 
their excellent optical absorption properties, SWNTs 
can cause long-term toxicity depending on the 
formulation characteristics, while Au nanoparticles 
can deform under photoacoustic irradiation, which 
leads to a shift in the optical absorption.47,48 
Furthermore, the potential toxicological effects of Au 
nanoparticles are hard to predict.49 
Our primary aim is to use PLGA-PFCE-ICG 
nanoparticles in cellular therapies. In this work, we 
focused on the imaging of primary human DCs as 
used in clinical vaccines. The PLGA-PFCE 
nanoparticles are readily taken up by DCs and 
typically colocalize with late endosomes.20 The 
nanoparticles show no toxicity and are safe for cell 
loading, which was shown with a standard viability 
assay (Fig. S2). Furthermore, we have previously 
shown that our nanoparticles show no side effects 
after in vivo injections up to 1-week post-injection.22 
We have looked at the effects of the nanoparticles on 
labelling primary murine and human cells in several 
publications, and never found any significant 
effect.19,21,50 With the PA measurement, the absorption 
peak of nanoparticle-loaded cells was detected at 800 
nm wavelength, which slightly differed from free 
nanoparticles PA peak absorption, a shift that can be 
caused by the cellular uptake and cellular pH.  
Retention of the ICG signal is an important factor 
for the imaging of cellular therapies. Christensen et al. 
performed an experiment where they incubated free 
ICG dye with monocytes.51 They then looked at the 
changes in the fluorescent signal within the 
ICG-loaded cells, observing a gradual and continuous 
decrease in fluorescence intensity and complete loss 
of signal within 12 hours.51 In our signal retention 
experiments, we showed that the signal coming from 
the nanoparticle-loaded DCs can be detected at least 
up to 48 h. This further shows the application of 
PLGA-PFCE-ICG nanoparticles for longitudinal cell 
tracking. Overall, the results of our study show great 
promise for the feasible use of PLGA-PFCE-ICG 
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nanoparticles for cell imaging and cell tracking using 
multimodal imaging. 
Conclusion 
In this work, we demonstrated the application of 
PLGA-PFCE-ICG nanoparticles as contrast agents in 
multimodal imaging, with the focus on PAI, 19F MRI, 
and fluorescence imaging, with a sensitivity of at least 
0.1x106 cells for primary human dendritic cells. The 
results show that our nanoparticle gives a clear signal 
when imaged with these imaging modalities, both in 
vitro and in vivo, and when loaded into cells. 
Furthermore, we present a reproducible method of 
formulation of nanoparticles, with characteristics 
suitable for clinical use (GMP-grade manufacturing). 
PLGA-PFCE-ICG nanoparticles can be potentially 
used as non-invasive labels for cell tracking and 
lymph node detection, as they do not show any 
toxicity after cell loading and are stable even with 
long incubation times with the cells. PLGA-PFCE-ICG 
nanoparticles can be further adapted for targeting 
with the addition of targeting ligands during particle 
synthesis. Finally, these nanoparticles are approved 
for a clinical cell tracking trial, making the translation 
for photoacoustics feasible.  
Materials and Methods  
Materials 
Following chemicals were used: 
poly(D,L-lactide-co-glycolide) (PLGA) resomer RG 
502H, lactide:glycolide molar ratio 50:50 (Evonik), 
dichloromethane (Merck, Darmstadt, Germany), 
perluoro-15-crown-5-ether (PFCE) (Exfluor, USA), 
Prohance (Bracco, Germany), poly(vinyl alcohol) 
(PVA, 80% hydrolized) (Sigma-Aldrich St. Louis, MO, 
USA), indocyanine green (IC-GREEN® for injection, 
USP, Akorn, USA). For cell culture X-VIVO 15 
medium (Lonza, Belgium) or RPMI 1640 medium 
(Gibco®, Thermo Fisher, UK) was used. Ultrapure 
water was purified with Synergy® water purification 
system. 
Particles synthesis 
Particles were prepared using a miniemulsion 
synthesis technique. Briefly, PLGA (200 mg), was 
dissolved in 6 mL of dichloromethane, followed by 
the addition of 1800 μL PFCE, 2 mg of indocyanine 
green and 3.6 mL Prohance. The organic phase was 
added to 50 mL of aqueous solution of surfactant (2,5 
wt.-%) and emulsified for 3 minutes with the use of 
probe sonicator (Q7000, microtip 6.4 mm, Qsonica 
LCC, USA) at 90% amplitude. Sonication was 
followed by overnight evaporation of solvent at room 
temperature. Next, the particles were collected by 
centrifugation, washed several times with deionized 
water, and then freeze-dried.  
Particle characterization 
Dynamic light scattering was measured on 
Nanotrac Flex In-situ Analyser (Microtrac, Germany) 
at concentrations of 0.1 mg/mL. The fluorine content 
of nanoparticles was measured with Nuclear 
Magnetic Resonance spectroscopy (Bruker Avance III 
400 MHz NMR spectrometer equipped with a BBFO+ 
probe). The samples were prepared with 500 μL 
deuterium oxide (D2O) and 100 μL 0.5 vol-% 
trifluoroacetic acid (TFA) and transferred to NMR 
tubes. Data analysis was carried out with Mestrenova 
10.0.2.  
ICG encapsulation was measured with 
spectrophotometry (JASCO V-630 UV-Vis 
spectrophotometer). Several nanoparticle samples at a 
concentration of 1 mg/mL were placed in a cuvette 
and analyzed with the spectrophotometer, with the 
absorption spectrum set at 670-980 nm. Obtained data 
were converted to concentrations by means of 
calibration curves. The encapsulation efficiency was 
calculated using following formula:  
𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 (%)= 𝐴𝐴𝐴𝐴𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 𝐸𝐸𝐸𝐸 𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝑒𝑒 𝑒𝑒𝐸𝐸𝐸𝐸 
𝐴𝐴𝐴𝐴𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 𝐸𝐸𝐸𝐸 𝑒𝑒𝐸𝐸𝐸𝐸 𝐸𝐸𝐸𝐸𝐸𝐸𝑒𝑒 𝐸𝐸𝐸𝐸𝑓𝑓 𝐸𝐸ℎ𝐸𝐸 𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸ℎ𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 x100 
Cryogenic Scanning Electron Microscopy was 
done at JEOL 6330 Cryo Field Emission Scanning 
Electron Microscope (FESEM). For cryo-SEM analysis, 
the samples (10 mg/mL, 8 µL) were pipetted in 2 
rivets, which were then placed together. Next, the 
samples were frozen in liquid nitrogen slush and 
placed in an Oxford Alto 2500 cryo station with a 
cryo-transfer device. There the top rivet was broken 
and the sample was heated to -95°C for 5 minutes, 
followed by a coating of 60/40 Au/Pd and transfer to 
the Cryo-SEM.  
The PA properties of nanoparticles were 
measured with spectroscopic PAI by scanning the 
excitation wavelength from 680 to 970 nm in 5 nm 
increments. The spectra of nanoparticles were 
compared to that of free dye. 
Cell culture and labeling 
Peripheral blood mononuclear cells (PBMCs) 
were isolated from buffy coats of healthy individuals 
after informed consent, using ficoll density 
centrifugation (Lymphoprep, STEMCELL Techno-
logies, Vancouver, Canada). Adherent monocytes 
were cultured in X-VIVO 15 medium supplemented 
with 2% human serum, and in the presence of 
interleukin-4 (300 U/mL) and granulocyte-monocyte 
colony stimulating factor (450 U/mL) to obtain 
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immature dendritic cells (DCs). Day 3 cells were 
harvested and labeled with nanoparticles 
(resuspended in PBS right before the labeling) at 
concentration 2 mg of nanoparticles/ 1x106 cells. The 
cells were then incubated at 37°C in 6-well plates for 
several time points, based on the assay. For the in vitro 
and in vivo imaging sessions, the excess of the label 
was removed and cells were gently washed, 
harvested and resuspended in PBS. 
Cell staining and confocal microscopy 
The uptake of nanoparticles containing nile blue 
dye was studied with confocal microscopy. Day 
3-DCs were incubated at 37°C for 24 hours on glass 
coverslips (20,000 cells per coverslip). After 
incubation the excess of the label was removed, the 
coverslips with attached cells were gently washed 
with PBS, and then the cells were fixed with 2% 
paraformaldehyde. Labelled cells on coverslips were 
permeabilized in CLSM buffer +0.1% Saponin, stained 
with EEA1-specific primary antibody (Ab), followed 
by staining with isotype-specific AlexaFluor- 
conjugated secondary Ab for early endosomes, 
phalloidin-488 for cell membrane, and DAPI for the 
nucleus. Stained cells were then imaged with 
Olympus FV1000 Confocal Laser Scanning 
Microscope. Acquired images were processed in the 
ImageJ2 program.  
Signal stability test 
The photoacoustic stability of the ICG signal was 
measured in the polyurethane tubing. Here, 
PLGA-PFCE-ICG nanoparticles at the concentration 
of 10 mg/mL were injected into the tubing. In another 
tubing, free ICG dye was injected. The concentration 
of the dye used resembled the amount of dye in the 
nanoparticles. Both tubes were then exposed to 10 
minutes of continues photoacoustic irradiation at 800 
nm. The acquired data were then plotted with the use 
of Origin data analysis software (Origin 9.1). 
Cell viability 
To investigate the influence of labelling on cell 
viability we performed an MTT assay. For this, 1x106 
cells were incubated in the presence of 
PLGA-PFCE-ICG nanoparticles for 72 hours. Here, 
two different samples were tested in triplicates, 
including positive and negative control. After 
incubation, the excess of the label was removed by 
gentle washing with PBS. Next, cells were collected 
and placed in a 96-well flat-bottom plate, washed two 
times with PBS (100 µL/well) with centrifugation of 2 
minutes between each wash. Next, 60 µL x-vivo 
medium with 10 µL MTT (3-(4,5-Dimethylthiazol- 
2-yl)-2,5-Diphenyltetrazolium Bromide) (concen-
tration 4 mg/mL) was added to each well, followed 
by 1-hour incubation at 37°C. After incubation, the 
plate was centrifuged for 2 minutes and 100 µL of 
lysis buffer (isopropanol, 10% SDS, 2N HCL, 
deionized water) was added to each well, and the 
plate was incubated for 15 minutes in dark at room 
temperature. Before the measurement, samples were 
resuspended to remove any precipitate of crystals. 
The plate was measured with iMark™ microplate 
reader (Bio-Rad, the Netherlands) at 595 nm. Cell not 
loaded with nanoparticles were used as negative 
control and cells treated with 0.2% Triton X-100 were 
used as a positive control. 
Signal retention 
In fluorescence imaging 
Day-3 moDCs were labelled with PLGA-PFCE- 
ICG nanoparticles as described above. The cells were 
then incubated with the label for 72 h. At 72 h time 
point, the excess of the label was removed and cells 
were gently washed with PBS. Part of the cells 
(0.7x106) was incubated in fresh medium without the 
label for additional 24 h. Remaining 0.7x106 loaded 
cells were harvested, resuspended in 100 µL PBS and 
imaged with IVIS LUMINA (exc. 745 nm, exposure 
time 1 second). After 24 h incubation second part of 
the cells, was harvested, resuspended in 100 µL PBS, 
and imaged. 
In flow cytometry 
Day-3 moDCs were labelled with 
PLGA-PFCE-ICG nanoparticles and incubated with 
the label for 24, 48, and 72 h. The non-labeled cells 
were used here as a control. At each time point, the 
excess of the label was removed, the cells were gently 
washed with PBS, and the cells were either measured 
immediately or incubated further for 24 h, in fresh 
medium without the label. Before the measurement, 
the cells were harvested, washed in PBS, then 
resuspended in 100 µL PBA (PBS+BSA+NaN3). 10 µL 
of propidium iodide was added to each sample prior 
the measurement to label the dead cells. The cells 
were then measured with BD FACSVerse™ flow 
cytometer (BD Biosciences) to detect the PLGA- 
PFCE-ICG positive cells. 
Imaging modalities 
Photoacousitc imaging was performed on the 
Vevo® 2100 LAZR Imaging scanner (VisualSonics®, 
Inc., Toronto, Canada) equipped with an LZ250 21 
MHz transducer. Fluorescent imaging was done on 
IVIS LUMINA in vivo imaging system with the 
excitation set to 745 nm and emission set to ICGreen. 
19F Magnetic Resonance Imaging (MRI) was 
performed on 11 T MRI scanner (Biospec, Bruker, 
Ettlingen, Germany). Fluorine image was done using 
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bSSFP sequence, FOV 60, matrix 32, 4 4 mm slices, TR 
2.814, TE 1.407, FA 90, RF phase advance 180, 1300 
averages, Power 1.2, Fre -91.8 ppm, 25 kHz 
bandwidth, max gain, and scan duration of 10 
minutes. 
In vitro clinical 19F MRI was performed on a 
Prisma 3 T clinical scanner (Siemens Healthcare 
GmbH, Erlangen, Germany), using an in-house build 
dual channel coil. The phantom consisted of a volume 
of physiological conducting fluid and a 500 mL 0,3% 
NaCl infusion bag, with the clinically applicable 19F 
phantom in between. The 19F phantom consisted of a 2 
mL Eppendorf tube filled with a homogenous 
suspension of PLGA-PFCE-ICG nanoparticles in PBS 
at a 1 mg/mL concentration. Proton imaging was 
done with a T1-weighted 3D FLASH sequence, matrix 
260x352, voxel size 0.8x0.8 mm, slice thickness 2 mm, 
TR 13 ms, TE 4.76 ms, flip angle 25 degrees, imaging 
frequency 123.236271 MHz. Fluorine imaging was 
done using an optimized RARE sequence; matrix 
64x64, voxel size 7.8x7.8 mm, slice thickness of 1 cm, 
TR 4000 ms, TE 12 ms with center K-space filling, 
turbo factor 21, 32 averages, imaging frequency 
115.946923 MHz, with a total scan duration of 6:30 
min. Fluorine images where upscaled to the 1H 
resolution. 
In vitro imaging  
For the phantom experiments, nanoparticles 
were resuspended shortly before the measurement in 
PBS at various concentrations (10-150 mg/mL) and 
placed in wells of 8% gelatin gel phantom followed by 
photoacoustic imaging. Cells loaded with 
nanoparticles were also imaged in a gel phantom.  
In vivo imaging 
Wild-type C57Bl/6J female mice were obtained 
from Charles River Laboratory and maintained under 
specific pathogen-free conditions at the Central 
Animal Laboratory in Nijmegen, Netherlands. 
Experiments were performed according to the 
guidelines for animal care of the Nijmegen Animal 
Experiments Committee (DEC 2013-243). 
Prior to the experiment, mice were shaved to 
avoid hair absorption and to facilitate the injections 
and imaging sessions. 40 µl of nanoparticles in PBS at 
concentration 100 mg/mL or 0.1 x106 and 1x106 cells 
(in 30 µl PBS) loaded with nanoparticles were injected 
into a mouse thigh muscle under ultrasound 
guidance, followed by the photoacoustic and 
fluorescent imaging. Furthermore, free nanoparticles 
and nanoparticle-loaded cells (0.1 x106 and 1x106) 
were injected intramuscularly, followed by 19F MR 
imaging. 
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